Myriad Genetics, Inc. Hires JPMorgan to Explore Splitting Business

Aug. 19 (Bloomberg) -- Myriad Genetics Inc. hired the investment bank JPMorgan Chase & Co. to explore separating Myriad’s drug-development and genetic-testing businesses after its experimental treatment for Alzheimer’s disease failed.

MORE ON THIS TOPIC